Study of YELIVA™(ABC294640) for prevention of mucositis in head and neck cancer patients

Trial Profile

Study of YELIVA™(ABC294640) for prevention of mucositis in head and neck cancer patients

Planning
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs ABC 294640 (Primary)
  • Indications Mucositis
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Apr 2017 According to a RedHill Biopharma media release, this trial is expected to initiate in the third quarter of 2017.
    • 23 Feb 2017 According to a RedHill Biopharma media release, this trial is expected to initiate in mid-2017.
    • 05 Oct 2016 This trial is planned to be commenced in the first quarter of 2017, as reported by a RedHill Biopharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top